BLOOD & BIOLOGICS: 6949W.Barry Miskin, M.D./Palm Beach Research Center, West Palm Beach, FL, Aug. 4 (Office of Compliance and Bio-logics Quality). FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. addressed concerns regarding clinical studies following a review of five protocols during an inspection. After evaluating the center=s 483 response, forwarded from the Florida District Office, CBER CB·er n. One that uses a CB radio. found the reply adequate on some points and inadequate on others, while some items were not addressed at all. The agency cited deficiencies in the protocols, informed consent, case histories and source data documentation. In addition, the letter referred to Apatterns@ at the site indicating that Asome subjects were entered into studies while meeting ineligibility INELIGIBILITY. The incapacity to be lawfully elected. 2. This incapacity arises from various, causes, and a person may be incapable of being elected to one office who may, be elected to another; the incapacity may also be perpetual or temporary. criteria, followed in some cases by sponsor exceptions of the subjects.@ FDA said the deficiencies suggested Alack a·lack interj. Used to express sorrow, regret, or alarm: "'Las and fearful alack of control@ and Aa lack of understanding@ of procedures pertaining per·tain intr.v. per·tained, per·tain·ing, per·tains 1. To have reference; relate: evidence that pertains to the accident. 2. to investigational new drugs. In addition, the agency questioned an employee=s status as a registered medical assistant, since professional associations could not verify this. Miskin was asked to submit a time frame for completing his proposed SOPs. The inspection ended April 17; the start-ing date was not disclosed. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion